User:Othrowt/sandbox

From Wikipedia, the free encyclopedia

Analeptic[edit]

Doxapram

An analeptic, in medicine, is a central nervous system stimulant medication. The term analeptic typically refers to respiratory analeptics (for example, doxapram). These drugs act on the central nervous system to stimulate the breathing muscles, increase respiration. Analeptics can also be used as convulsants, with low doses causing patients to experience heightened awareness, restlessness and tachypnoea.[1] The primary medical use of these drugs is as an anesthetic recovery tool or to treat emergency respiratory depression.[2] Other drugs of this category are prethcamide, pentylenetetrazole, and nikethamide. Nikethamide is now withdrawn due to risk of convulsions.[3]

History[edit]

After its introduction in the early 20th century analeptics were used to study the newly life threatening topological problem of the barbiturate overdose. In their early use they concentrated on stimulants (camphor and caffeine), between the 1930's and 1960's the production of synthetic analeptics (nikethamide, pentylenetetrazol, bemegride, amphetamine, and methylphenidate) allowed for the treatment of barbiturate antidotes. Recently, analeptics have been turned to the treatment of ADHD due to more efficient ways to treat barbiturate overdoses.[4]

One of the first widely used analeptics was strychnine, which causes CNS excitation by antagonizing the inhibitory neurotransmitter glycine[5]. Strychnine is subcategorized as a convulsant along with picrotoxin and bicuculline. Strychnine was used until the early 20th century, when it was found to be a highly toxic convulsant. Strychnine is now available as a rodenticide as well as an adulterant in drugs such as heroin[6]. The other two convulsants antagonize GABA receptors, but neither are commonly accessible today[7].

Doxapram has begun to fade into obscurity in humans even though it is an effective CNS and respiratory stimulant. The use has declined primarily because of shorter lasting anesthetic agents becoming more abundant, but also because some research has shown potential side effects in infants[8][9]. Some studies on preterm infants found that doxapram causes decreased cerebral blood flow and increases cerebral oxygen requirement. This resulted in these infants having higher chances of developing mental delays than infants not treated with the drug[10]. Thus, doxapram has been eliminated from many treatments for humans because of its potential dangers.

Clinical use[edit]

Doxapram

Analeptics have been used throughout history as central nervous system stimulants helping to overcome depression, while methylphenidate can be used to treat ADHD in many patients. They can also be used to increase the speed of recovery from propofol, remifentanil, and sevoflurane. In clinical settings, analeptics such as Doxapram have also been used to help patients recover from anesthesia better, as well as removing some of the potential negative side effects of potent anesthetics. Methylxanthines such as caffeine and theophylline also have significant clinical uses as central nervous system stimulants as well as respiratory stimulants.[11]

One major analeptic category is the category of xanthines. Caffeine and theophylline are the most widely used of these drugs. Large doses of these chemicals cause stimulation in the Central Nervous System and large doses stimulate respiration[12]. Newborns with respiratory distress are often given caffeine to increase respiration[13]. Theophylline is typically used as a bronchiole relaxer, however can also be used as a repertory stimulant in newborns. Xanthines are primarily used for newborns with apnea in order to stimulate respiration[14].

The side effects seen in xanthines are seen jittery, over energetic behavior, as well as potentially insomnia. Other side effects can include diuresis, gastrointestinal irritation, and rarely ringing in the ears. At high doses they can also cause psychological dependence[15].

Doxapram is an intravenous CNS and respiratory stimulant that is typically used to treat respiratory depression caused anesthesia or chronic obstructive pulmonary disease. Doxapram can also be used as a treatment for neonatal apnea, but it can be dangerous, so caution must be taken. Doxapram has been used to treat respiratory depression in drug overdoses; however, there are many drugs which this is not effective. The side effects of Doxapram are rare, however, with overdose, hypertension, tachycardia, tremors, spasticity, and hyperactive reflexes have been seen to occur[16].

Mechanism of action[edit]

Analeptics are a diverse group of medications which work through a variety of chemical pathways; however, there are three main mechanisms which analeptic medications work through in order to stimulate respiration. These are potassium channel blockers, ampakines, and serotonin receptor agonists.

Two common potassium channel blockers are Doxapram and GAL-021. Both act on potassium channels in Carotid Bodies. These cells are responsible for sensing low concentrations of oxygen and transmitting information to the central nervous system. Blocking the potassium channels on the membranes of these cells effectively reduces the membrane potential which in turn leads to voltage gated calcium channels being opened and neurotransmitter release which begins the process of relaying the signal to the central nervous system. Doxapram blocks background potassium channels in the TASK-family of potassium channels while GAL-021 blocks BK channels, or big potassium channels, which are activated by a change in membrane electron potential or by an increase in internal calcium.[17]

Ampakines are the second common form of analeptics which elicit a different mechanism for an analeptic response. They bind to AMPA receptors, or amino-3-hydroxy-5-methyl-D-aspartate receptors, within the pre-Bötzinger complex. The pre-Bötzinger complex is part of the ventral respiratory group and the induction of long term potentials in the postsynaptic membrane of these neurons leads to an increased respiratory rate. AMPA receptor ligand is glutamate and ampakines mirror glutamate's interaction with the receptors. Ligand binding causes AMPA receptors to open and allow for sodium ions to flow through the cell, leading to depolarization and signal transduction. At this time, CX717 is the most successful ampakine in human trials and has very few side effects.[18]

The third common mechanism which analeptics take advantage of is to act as serotonin receptor agonists. Buspirone and Mosapride successfully increased respiration in animals by agonizing serotonin receptors which are G protein coupled receptors which, upon activation, induce a secondary messenger cascade and in this case that cascade leads to an analeptic response.[19]

Related research[edit]

Analeptics have recently been used to better understand the treatment of a barbiturate overdose. Through the use of agents researchers were able to treat obtundation and respiratory depression.[20]

Methylxanthines caffeine and theophylline[edit]

Structurally, caffeine and theophylline are classified as methylated xanthines. The drug caffeine citrate (Cafcit) is a derivative of caffeine. Cafcit is synthesized by the chemical reaction between anhydrous caffeine with citric acid. Caffeine citrate functions in the same manner as regular caffeine, but it takes effect quicker due to the addition of anhydrous citrate.

The three most prevalent clinical analeptic uses of caffeine are in the treatment of asthma, apnea of prematurity, and bronchopulmonary dysplasia in newborn infants.[21] Caffeine is a weak bronchodilator, which explains the relief of the effects of asthma. There is preliminary research that indicates that caffeine reduces the incidence of cerebral palsy and cognitive delay, but additional research is needed here.[22] Apnea of prematurity is officially described as a cessation of breathing for more than 15-20 seconds, usually accompanied by bradycardia and hypoxia.[23] This cessation of breathing is due to the underdevelopment of the body's respiratory control center, the medulla oblongata in premature infants.

Ample research also suggests that caffeine significantly reduces the occurrence of bronchopulmonary dysplasia, which is a chronic lung disorder defined by the need for supplemental oxygen after a postmenstrual age of 36 weeks.[24] Bronchopulmonary dysplasia is common in infants with low birth weight (<2500g) and very low birth weight (<1500g) who received mechanical ventilator machines to help manage respiratory distress syndrome. Currently, there is no treatment for bronchopulmonary dysplasia, as it is generally considered that the risks of treatment outweigh the necessity for using a mechanical ventilator. Caffeine only reduces occurrence.

With respect to breathing, caffeine acts a competitive adenosine antagonist. Researchers discovered this by administering adenosine or its derivatives are finding that the effects were opposite to that of caffeine. Increased adenosine levels are known to cause depression of spontaneous electrical activity of the neurons, inhibition of neurotransmission, and increased release of neurotransmitters. Adenosine inhibits respiratory drive by blocking the electrical activity of respiratory neurons.[25] Caffeine, as a adenosine antagonist, stimulates these respiratory neurons causing enhancement of respiratory minute volume.

Theophylline is no longer used as a respiratory analeptic in newborn infants. Theophylline has a very narrow therapeutic index, so its dosages must be supervised by direct measurement of serum theophylline levels to avoid toxicity.

References[edit]

  1. ^ Young, Simon; Campbell, Ryan (January 2015). "Central nervous system stimulants: basic pharmacology and relevance to anaesthesia and critical care". Anaesthesia & Intensive Care Medicine. 16 (1): 21–25. doi:10.1016/j.mpaic.2014.10.005. Retrieved 16 February 2015.
  2. ^ Heggem, Brittany (July 2011). "Doxapram". Journal of Exotic Pet Medicine. 20 (3): 237–240. doi:10.1053/j.jepm.2011.04.011. Retrieved 16 February 2015.
  3. ^ "Analeptic". A Dictionary of Nursing. Encyclopedia.com (mirror). 2008. Retrieved 2008-06-08.
  4. ^ Wax, P. M. "Analeptic Use in Clinical Toxicology: A Historical Appraisal." J Toxicol Clin Toxicol (1997): 203-09. PubMed. Web. 15 Mar. 2015.
  5. ^ Young, Simon; Campbell, Ryan (January 2015). "Central nervous system stimulants: basic pharmacology and relevance to anaesthesia and critical care". Anaesthesia & Intensive Care Medicine. 16 (1): 21. doi:10.1016/j.mpaic.2014.10.005. Retrieved 16 February 2015.
  6. ^ Young, Simon; Campbell, Ryan (January 2015). "Central nervous system stimulants: basic pharmacology and relevance to anaesthesia and critical care". Anaesthesia & Intensive Care Medicine. 16 (1): 21–25. doi:10.1016/j.mpaic.2014.10.005. Retrieved 16 February 2015.
  7. ^ Young, Simon; Campbell, Ryan (January 2015). "Central nervous system stimulants: basic pharmacology and relevance to anaesthesia and critical care". Anaesthesia & Intensive Care Medicine. 16 (1): 21–25. doi:10.1016/j.mpaic.2014.10.005. Retrieved 16 February 2015.
  8. ^ McLeod, James; Hewitt, Matthew; Golder, Francis (1 November 2013). "Respiratory stimulant drugs in the post-operative setting". Respiratory Physiology & Neurobiology. 189 (2): 397. doi:10.1016/j.resp.2013.06.010. Retrieved 16 February 2015.
  9. ^ Heggem, Brittany (July 2011). "Doxapram". Journal of Exotic Pet Medicine. 20 (3): 237–240. doi:10.1053/j.jepm.2011.04.011. Retrieved 16 February 2015.
  10. ^ Heggem, Brittany (July 2011). "Doxapram". Journal of Exotic Pet Medicine. 20 (3): 237–240. doi:10.1053/j.jepm.2011.04.011. Retrieved 16 February 2015.
  11. ^ Kim, Y. J., H. Lee, C. H. Kim, G. Y. Lee, H. J. Baik, and J. I. Han. "Effect of Flumazenil on Recovery from Anesthesia and the Bispectral Index after Sevoflurane/fentanyl General Anesthesia in Unpremeditated Patients." Korean J Anesthesiol (2012): 19-23. PubMed. Web. 12 Mar. 2015.
  12. ^ Kee, Joyce L.; Hayes, Evelyn; McCuistion, Linda E. (2012). Pharmacology : a nursing process approach (7th ed.). St. Louis, MO.: Elsevier Saunders. p. 289. ISBN 143771711X.
  13. ^ Kee, Joyce L.; Hayes, Evelyn; McCuistion, Linda E. (2012). Pharmacology : a nursing process approach (7th ed.). St. Louis, MO.: Elsevier Saunders. pp. 289–290. ISBN 143771711X.
  14. ^ Kee, Joyce L.; Hayes, Evelyn; McCuistion, Linda E. (2012). Pharmacology : a nursing process approach (7th ed.). St. Louis, MO.: Elsevier Saunders. p. 290. ISBN 143771711X.
  15. ^ Kee, Joyce L.; Hayes, Evelyn; McCuistion, Linda E. (2012). Pharmacology : a nursing process approach (7th ed.). St. Louis, MO.: Elsevier Saunders. p. 290. ISBN 143771711X.
  16. ^ Kee, Joyce L.; Hayes, Evelyn; McCuistion, Linda E. (2012). Pharmacology : a nursing process approach (7th ed.). St. Louis, MO.: Elsevier Saunders. p. 291. ISBN 143771711X.
  17. ^ Dahan, Albert. "Opioid-induced respiratory depression: reversal by non-opioid drugs". NCBI.
  18. ^ Dahan, Albert. "Opioid-induced respiratory depression: reversal by non-opioid drugs". NCBI.
  19. ^ Dahan, Albert. "Opioid-induced respiratory depression: reversal by non-opioid drugs". NCBI.
  20. ^ Kim, Y. J., H. Lee, C. H. Kim, G. Y. Lee, H. J. Baik, and J. I. Han. "Effect of Flumazenil on Recovery from Anesthesia and the Bispectral Index after Sevoflurane/fentanyl General Anesthesia in Unpremeditated Patients." Korean J Anesthesiol (2012): 19-23. PubMed. Web. 12 Mar. 2015.
  21. ^ Nehlig, Astrid (June 2, 1992). "Caffeine and the central nervous system:mechanisms of action, biochemical, metabolic and pyschostimulant effects". Brain Research Reviews. 17: 139–170.
  22. ^ Schmidt, Barbara (November 8, 2007). "Long-Term Effects of Caffeine Therapy for Apnea of Prematurity". New England Journal of Medicine. 357 (19): 1893–1902.
  23. ^ Schmidt, Barbara (May 18, 2006). "Caffeine Therapy for Apnea of Prematurity". New England Journal of Medicine. 354 (20): 2112–2121.
  24. ^ Barbara, Schmidt (May 18, 2006). "Caffeine Therapy for Apnea of Prematurity". New England Journal of Medicine. 354 (20): 2112–2121.
  25. ^ Nehlig, Astrid (June 2, 1992). "Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects". Brain Research Reviews. 17: 139–170.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Othrowt/sandbox&oldid=910632361"